Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:
馬薩諸塞州劍橋和紐約，2024 年 4 月 3 日（GLOBE NEWSWIRE）— 黑鑽療法有限公司 納斯達克股票代碼：BDTX）是一家臨床階段的腫瘤學公司，正在開發針對癌症患者致癌突變家族的MasterKey療法，該公司今天宣佈參加即將舉行的投資者會議。總裁兼首席執行官Mark Velleca，醫學博士，博士的演講詳情如下：
- 23rd Annual Needham Virtual Healthcare Conference presentation at 8:00am ET on Wednesday, April 10, 2024
- Stifel Virtual Targeted Oncology Forum fireside chat at 10:00am ET on Tuesday, April 16, 2024
- Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, in Boston, Mass.
- 第 23 屆年度 Needham 虛擬醫療會議將於美國東部時間 2024 年 4 月 10 日星期三上午 8:00 發表演講
- Stifel 虛擬靶向腫瘤學論壇將於美國東部時間 2024 年 4 月 16 日星期二上午 10:00 進行爐邊談話
- 派珀·桑德勒春季生物製藥研討會將於2024年4月17日星期三在馬薩諸塞州波士頓舉行。
Webcasts will be available at the start of the presentations on the investor relations section of the Company's website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.
網絡直播將在公司網站的投資者關係部分的演講開始時播出， www.blackdiamondther。演示文稿的重播也將在網站上提供並存檔90天。
About Black Diamond Therapeutics
關於黑鑽療法
Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company's MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com
Black Diamond Therapeutics是一家臨床階段的腫瘤學公司，專注於開發MasterKey療法，以解決臨床驗證的靶標中的致癌突變家族。該公司的MasterKey療法旨在針對廣泛的基因定義的患者群體，克服耐藥性，最大限度地減少野生型介導的毒性，並具有大腦穿透力來治療中樞神經系統疾病。該公司正在推進兩個臨床階段的項目：BDTX-1535，一種靶向表皮生長因子突變體NSCLC和GBM的第四代表皮生長因子MasterKey抑制劑，以及一種針對實體瘤KRAS、NRAS和BRAF改變的腦穿透性RAF MasterKey抑制劑 BDTX-4933。欲了解更多信息，請訪問 www.blackdiamondther
Contacts
聯繫人
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com
對於投資者：
馬里奧·科爾索，Black Diamond Therapeutics投資者關係主管
mcorso@bdtx.com
For Media:
media@bdtx.com
對於媒體：
media@bdtx.com